Controlled Nucleation for a Monoclonal Antibody Formulation—A Case Study

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2015
Volume 2015 eBook
Issue 2

This study evaluates the impact of controlled nucleation on the ability to optimize a lyophilization cycle for a monoclonal antibody formulation.

 

This study evaluates the impact of controlled nucleation on the ability to optimize a lyophilization cycle for a monoclonal antibody formulation.

Download

Pharmaceutical Technology’s 2015 Bioprocessing and Sterile Manufacturing eBook


 

Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content